VR MED

VR MED

The First VR Solution In MedTech

VR MED is the first medical device in the world to employ VR technology for a wide range of uses. It has similar success not only in ophthalmology, but also neurology and rehabilitation. All you need for the transformation is to put in the required software and configure the system.This equipment covers a large part of the clinic’s needs with VR technology.Today, the VR headset is capable of replacing 40% of all instrument functionality ophthalmology room, having a cost of 6 times less than the cost equipment "Golden Standard". Development of new directions of diagnostics and treatment of patients is conducted.The technology is patented. VRMD tokens will become an internal currency of the platform, allowing users to get software to extend the functionality of the gadget and support new developments on the platform.

About VR MED
Short Brief about VR MED ICO PROJECT with a score of 6.0, and this report was written on 5 July, 2018.
Take note that the information you see right now may change.

ICO PROJECT was alive at 5 July, 2018

Startup END DATE was 5 July, 2018

ICO PROJECT has chosen Ethereum token staging.

Company has 3 consultants.
Konstantin Kotlyar.


Alexey Antonov (MD,Ph.D., leading expert).
He was seen working at SONM (Marketing and Financial Advisor) ICO PROJECT
Team
CEO, Co-founder, patent author
COO, SAP, HP, PwC, Philips
Lead Medical Business Developer
Investment Director, Co-founder Aktivo, MTS
Medical leader, MD, Co-founder, Author of patents
CTO, Co-founder, Patent author
Lead Design Engineer, Model Specialist
VR developer, Graphics Programmer Red Machine LLC, W.E.L.L., Diamond Scent Ltd, BioLink
Optical Designer, Optical system modeling
Marketing director
Pr & Marketing specialist
Senior engineer
advisors
MD,Ph.D., leading expert
International Business Development, Bionesty Ltd., Representative of VR MED in EU, UK
PhD, Professor of biomedical engineering FH Aachen University of Applied Sciences
Milestones
06.2016
Start of the development of the VR headset and programming suitable for medical use.
12.16 - 02.17
Patent granted in Russia. Start of process to receive international patents.
02.17 - 04.17
Creation of pilot model of equipment and software for screening for early detection of glaucoma and other conditions with peripheral vision defects. Successful experimental outcomes in the Institute of Eye Diseases at the Russia Academy of Sciences.
04.17
Participation at international presentations in Lisbon and Bahrain. Introduction of the device.
05.17-07.17
Successful approval process for the device and software at the FH Aachen University of Applied Sciences.
07.17-10.17
Development of the Alpha version of the device, with the capability of providing solutions in ophthalmology (measurement of peripheral vision, diagnosis of glaucoma markers).
03.18 - 06.18
Development of the device final version (technical and usage fine-tuning), construct improvements.
06.18 - 08.18
Standard ISO 12866-2011. Industrial design development.
08.18 - 12.18
Certification of software “Perimeter”: Creation of a universal design for diagnosis of a range of visual functions (through early diagnosis of glaucoma and other peripheral vision field defects).
04.18 - 09.18
Entrance to the world market: Undergo approval process in India and China clinics; obtain international ISO certification.
05.18 - 07.19
Upload of users’ data to the platform. Distribution of the device in the European Union, Russia and Asia; Launch of decentralized platform; The 100% functional Perimeter becomes the “gold standard” in ophthalmic diagnosis.
05.18 - 07.19
Widening of device functionality to include usage in neurology and rehabilitation.
Financial
token info
Token Name VRMD
Token Platform Ethereum
Token Amount For Sale 2,000,000
Ico Token Price 0.2500 USD
investment info
Fundraising Value Unknown
Personal Cap Min 100 USD
Accept Currencies BTC, ETH, LTC, Fiat
Soft Cap 1,000,000 USD
Hard Cap 5,000,000 USD
Widget
HORISONTAL
SQUARE
height - 80 px
width - 270 px
put this code to your website
Cookies help us deliver our services. By using our services, you agree to our use of cookies.